

#13
DmT
9501

EXPRESS MAIL NO.: EL 501 641 450 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Stein and Yang

Application No.: 09/593,288

Filed: June 13, 2000

For: MITOGEN-ACTIVATED PROTEIN
KINASE KINASE MEK6 AND
METHODS OF USE THEREOF

Group Art Unit: 1633

Examiner: Y. Pak

SEP 10 2001

TECH CENTER 1600/2900

Attorney Docket No.: 10624-021-999
(Formerly 860098.403C1)

**TRANSMITTAL OF POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE
INTEREST AND REVOCATION OF PRIOR POWER OF ATTORNEY**

Commissioner of Patents and Trademarks
Washington, DC 20231

S I R:

Pursuant to 37 C.F.R. § 1.36, Applicants submit herewith a Power of Attorney by Assignee of Entire Interest and Revocation of Prior Power of Attorney that provides Pennie & Edmonds LLP with power of attorney in connection with the present patent application.

Please direct all correspondence and telephone calls to Pennie & Edmonds LLP at the address indicated below.

Respectfully submitted,

by: *Jacqueline Benn*
Reg No. 43,492

Date: September 4, 2001

Anthony M. Insogna 35,203
(Reg. No.)

Anthony M. Insogna
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, NY 10036-2711
(212) 790-9090

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Stein and Yang

Application No.: 09/593,288

Filed: June 13, 2000

For: MITOGEN-ACTIVATED PROTEIN
KINASE KINASE MEK6 AND
METHODS OF USE THEREOF

Group Art Unit: 1633

Examiner: Not yet assigned

Attorney Docket No.: 10624-021-999
(Formerly 860098.403C1)

SEP 10 2001

TECH CENTER 1600/2900

REVOCATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents
Washington, D.C. 20231


S I R :

Signal Pharmaceuticals, Inc., owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified patent application by virtue of an assignment (or assignments) recorded on May 19, 1997, at Reel 8511, Frame 0059, hereby revokes all previous powers of attorney and appoints S. Leslie Misrock (Reg. No. 18872), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885),

Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them its attorneys, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all future correspondence to Pennie & Edmonds LLP, located at 1155 Avenue of the Americas, New York, N.Y. 10036-2711, and direct all telephone calls to Pennie & Edmonds LLP at (212) 790-9090.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "David Anderson", is written over a horizontal line.

Date: May 3, 2001

By: David Anderson, Ph.D.
Title: Chief Scientific Officer
Signal Pharmaceuticals, Inc.